Alamea Verwaltungs GmbH Acquires Shares of 16,894 Cellebrite DI Ltd. $CLBT

Key Points

• Alamea Verwaltungs GmbH acquired a new stake worth approximately $328,000 in Cellebrite DI Ltd. during the first quarter, purchasing 16,894 shares.
• Several institutional investors have increased their holdings in Cellebrite DI, with T. Rowe Price investing around $60.9 million, while Invesco and Handelsbanken Fonder also made significant buys.
• Analysts have adjusted their price targets downward with an average target price of $22.40, while maintaining a general consensus rating of "Buy" for the stock.

Alamea Verwaltungs GmbH acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 16,894 shares of the company's stock, valued at approximately $328,000.

Other institutional investors also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in Cellebrite DI in the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC acquired a new stake in Cellebrite DI in the first quarter valued at approximately $51,000. Virtus Advisers LLC acquired a new stake in Cellebrite DI in the first quarter valued at approximately $63,000. Gen Wealth Partners Inc acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $85,000. Finally, NewEdge Advisors LLC boosted its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock traded down $0.14 during trading on Thursday, hitting $16.37. 4,335,634 shares of the company's stock were exchanged, compared to its average volume of 1,690,974. The business has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $17.09. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of -21.54, a PEG ratio of 2.98 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm had revenue of $113.28 million during the quarter, compared to analysts' expectations of $112.33 million. During the same quarter last year, the company posted $0.10 earnings per share. The firm's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Finally, Lake Street Capital dropped their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of "Buy" and a consensus price target of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.